While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?
At the time of reception of this article (April 2, 2020), efforts to develop a specific vaccine against SARS-Cov-2, the causative agent of the coronavirus disease 2019 (COVID-19), had just begun trial phase 1, but full validation of this and other current developments is likely to take many more mon...
Main Author: | Francisco J. Barrantes |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Physiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphys.2020.00820/full |
Similar Items
-
Are new genome variants detected in SARS-CoV-2 expected considering population dynamics in viruses?
by: Ergoren Mahmut Cerkez, et al.
Published: (2021-01-01) -
SARS-CoV-2 Cellular Entry Is Independent of the ACE2 Cytoplasmic Domain Signaling
by: Thankamani Karthika, et al.
Published: (2021-07-01) -
Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins
by: Sai Priya Anand, et al.
Published: (2020-09-01) -
ACE2: the molecular doorway to SARS-CoV-2
by: Miriam Marlene Medina-Enríquez, et al.
Published: (2020-12-01) -
Effects of SARS-CoV-2 on the cardiovascular system: More issues to be addressed
by: Yang Liu
Published: (2020-07-01)